Biomarker Significance of Serum CXCL8, CXCL10 and CXCL16 in Breast Tumors of Iraqi Patients

The biomarker significance of three chemokines (CXCL8, CXCL10 and CXCL16) was evaluated in sera of 45 breast cancer (BC) and 28 benign breast lesion (BBL) patients, as well as 20 control women. Clinical stage and tumor expression of estrogen (ER), progesterone (PgR) and human epidermal growth factor...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Aseel F Khalaf [verfasserIn] Munawar A Al-naqqash [verfasserIn] Nada A Alawn [verfasserIn] Ali H Ad'hiah [verfasserIn]

Format:	E-Artikel
Sprache:	Arabisch ; Englisch

Erschienen:	2020

Schlagwörter:	Breast cancer, Benign breast lesion, CXCL8, CXCL10, CXCL16

Übergeordnetes Werk:	In: Baghdad Science Journal - College of Science for Women, University of Baghdad, 2017, 17(2020), 1(Suppl.)
Übergeordnetes Werk:	volume:17 ; year:2020 ; number:1(Suppl.)

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc Journal toc

DOI / URN:	10.21123/bsj.2020.17.1(Suppl.).0199

Katalog-ID:	DOAJ023964456

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ023964456
003	DE-627
005	20230307071740.0
007	cr uuu---uuuuu
008	230226s2020 xx \|\|\|\|\|o 00\| \|\|ara c
024	7		\|a 10.21123/bsj.2020.17.1(Suppl.).0199 \|2 doi
035			\|a (DE-627)DOAJ023964456
035			\|a (DE-599)DOAJ7b68ea0c0dce4556be436da6da38c644
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a ara \|a eng
100	0		\|a Aseel F Khalaf \|e verfasserin \|4 aut
245	1	0	\|a Biomarker Significance of Serum CXCL8, CXCL10 and CXCL16 in Breast Tumors of Iraqi Patients
264		1	\|c 2020
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a The biomarker significance of three chemokines (CXCL8, CXCL10 and CXCL16) was evaluated in sera of 45 breast cancer (BC) and 28 benign breast lesion (BBL) patients, as well as 20 control women. Clinical stage and tumor expression of estrogen (ER), progesterone (PgR) and human epidermal growth factor receptor-2 (HER-2) receptors were considered in this evaluation. The results demonstrated that CXCL8, CXCL10 and CXCL16 showed a significant increased median in BC and BBL patients compared to control (CXCL8: 47.3 and 25.7 vs. 15.0; CXCL10: 37.6 and 30.7 vs. 13.1; CXCL16; 27.9 and 25.2 vs. 19.2 pg/ml, respectively). The increased levels of CXCL8 and CXCL16 were more pronounced in triple-negative and HER-2 positive patients, respectively. Binary logistic regression analysis revealed that CXCL8 was a significant predictor of BC, and such prediction was more depicted in triple-negative patients. The receiver operating characteristic analysis also revealed that CXCL8 recorded an area under curve of 0.998 in BC patients. In conclusion, CXCL8 is a potential biomarker for BC, especially when ER, PgR and HER-2 expression is considered. In this context, the predictive significance of CXCL8 in influencing BC progression is suggested in triple-negative patients.
650		4	\|a Breast cancer, Benign breast lesion, CXCL8, CXCL10, CXCL16
653		0	\|a Science
653		0	\|a Q
700	0		\|a Munawar A Al-naqqash \|e verfasserin \|4 aut
700	0		\|a Nada A Alawn \|e verfasserin \|4 aut
700	0		\|a Ali H Ad'hiah \|e verfasserin \|4 aut
773	0	8	\|i In \|t Baghdad Science Journal \|d College of Science for Women, University of Baghdad, 2017 \|g 17(2020), 1(Suppl.) \|w (DE-627)756826632 \|w (DE-600)2727652-1 \|x 24117986 \|7 nnns
773	1	8	\|g volume:17 \|g year:2020 \|g number:1(Suppl.)
856	4	0	\|u https://doi.org/10.21123/bsj.2020.17.1(Suppl.).0199 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/7b68ea0c0dce4556be436da6da38c644 \|z kostenfrei
856	4	0	\|u http://bsj.uobaghdad.edu.iq/index.php/BSJ/article/view/3052 \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/2078-8665 \|y Journal toc \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/2411-7986 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a GBV_ILN_11
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_70
912			\|a GBV_ILN_73
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_171
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_370
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4335
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 17 \|j 2020 \|e 1(Suppl.)

Indexfelder

author_variant	a f k afk m a a n maan n a a naa a h a aha
matchkey_str	article:24117986:2020----::imresgiiacosrmxlcc1adxl6nrat
hierarchy_sort_str	2020
publishDate	2020
allfields	10.21123/bsj.2020.17.1(Suppl.).0199 doi (DE-627)DOAJ023964456 (DE-599)DOAJ7b68ea0c0dce4556be436da6da38c644 DE-627 ger DE-627 rakwb ara eng Aseel F Khalaf verfasserin aut Biomarker Significance of Serum CXCL8, CXCL10 and CXCL16 in Breast Tumors of Iraqi Patients 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The biomarker significance of three chemokines (CXCL8, CXCL10 and CXCL16) was evaluated in sera of 45 breast cancer (BC) and 28 benign breast lesion (BBL) patients, as well as 20 control women. Clinical stage and tumor expression of estrogen (ER), progesterone (PgR) and human epidermal growth factor receptor-2 (HER-2) receptors were considered in this evaluation. The results demonstrated that CXCL8, CXCL10 and CXCL16 showed a significant increased median in BC and BBL patients compared to control (CXCL8: 47.3 and 25.7 vs. 15.0; CXCL10: 37.6 and 30.7 vs. 13.1; CXCL16; 27.9 and 25.2 vs. 19.2 pg/ml, respectively). The increased levels of CXCL8 and CXCL16 were more pronounced in triple-negative and HER-2 positive patients, respectively. Binary logistic regression analysis revealed that CXCL8 was a significant predictor of BC, and such prediction was more depicted in triple-negative patients. The receiver operating characteristic analysis also revealed that CXCL8 recorded an area under curve of 0.998 in BC patients. In conclusion, CXCL8 is a potential biomarker for BC, especially when ER, PgR and HER-2 expression is considered. In this context, the predictive significance of CXCL8 in influencing BC progression is suggested in triple-negative patients. Breast cancer, Benign breast lesion, CXCL8, CXCL10, CXCL16 Science Q Munawar A Al-naqqash verfasserin aut Nada A Alawn verfasserin aut Ali H Ad'hiah verfasserin aut In Baghdad Science Journal College of Science for Women, University of Baghdad, 2017 17(2020), 1(Suppl.) (DE-627)756826632 (DE-600)2727652-1 24117986 nnns volume:17 year:2020 number:1(Suppl.) https://doi.org/10.21123/bsj.2020.17.1(Suppl.).0199 kostenfrei https://doaj.org/article/7b68ea0c0dce4556be436da6da38c644 kostenfrei http://bsj.uobaghdad.edu.iq/index.php/BSJ/article/view/3052 kostenfrei https://doaj.org/toc/2078-8665 Journal toc kostenfrei https://doaj.org/toc/2411-7986 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4335 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 17 2020 1(Suppl.)
spelling	10.21123/bsj.2020.17.1(Suppl.).0199 doi (DE-627)DOAJ023964456 (DE-599)DOAJ7b68ea0c0dce4556be436da6da38c644 DE-627 ger DE-627 rakwb ara eng Aseel F Khalaf verfasserin aut Biomarker Significance of Serum CXCL8, CXCL10 and CXCL16 in Breast Tumors of Iraqi Patients 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The biomarker significance of three chemokines (CXCL8, CXCL10 and CXCL16) was evaluated in sera of 45 breast cancer (BC) and 28 benign breast lesion (BBL) patients, as well as 20 control women. Clinical stage and tumor expression of estrogen (ER), progesterone (PgR) and human epidermal growth factor receptor-2 (HER-2) receptors were considered in this evaluation. The results demonstrated that CXCL8, CXCL10 and CXCL16 showed a significant increased median in BC and BBL patients compared to control (CXCL8: 47.3 and 25.7 vs. 15.0; CXCL10: 37.6 and 30.7 vs. 13.1; CXCL16; 27.9 and 25.2 vs. 19.2 pg/ml, respectively). The increased levels of CXCL8 and CXCL16 were more pronounced in triple-negative and HER-2 positive patients, respectively. Binary logistic regression analysis revealed that CXCL8 was a significant predictor of BC, and such prediction was more depicted in triple-negative patients. The receiver operating characteristic analysis also revealed that CXCL8 recorded an area under curve of 0.998 in BC patients. In conclusion, CXCL8 is a potential biomarker for BC, especially when ER, PgR and HER-2 expression is considered. In this context, the predictive significance of CXCL8 in influencing BC progression is suggested in triple-negative patients. Breast cancer, Benign breast lesion, CXCL8, CXCL10, CXCL16 Science Q Munawar A Al-naqqash verfasserin aut Nada A Alawn verfasserin aut Ali H Ad'hiah verfasserin aut In Baghdad Science Journal College of Science for Women, University of Baghdad, 2017 17(2020), 1(Suppl.) (DE-627)756826632 (DE-600)2727652-1 24117986 nnns volume:17 year:2020 number:1(Suppl.) https://doi.org/10.21123/bsj.2020.17.1(Suppl.).0199 kostenfrei https://doaj.org/article/7b68ea0c0dce4556be436da6da38c644 kostenfrei http://bsj.uobaghdad.edu.iq/index.php/BSJ/article/view/3052 kostenfrei https://doaj.org/toc/2078-8665 Journal toc kostenfrei https://doaj.org/toc/2411-7986 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4335 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 17 2020 1(Suppl.)
allfields_unstemmed	10.21123/bsj.2020.17.1(Suppl.).0199 doi (DE-627)DOAJ023964456 (DE-599)DOAJ7b68ea0c0dce4556be436da6da38c644 DE-627 ger DE-627 rakwb ara eng Aseel F Khalaf verfasserin aut Biomarker Significance of Serum CXCL8, CXCL10 and CXCL16 in Breast Tumors of Iraqi Patients 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The biomarker significance of three chemokines (CXCL8, CXCL10 and CXCL16) was evaluated in sera of 45 breast cancer (BC) and 28 benign breast lesion (BBL) patients, as well as 20 control women. Clinical stage and tumor expression of estrogen (ER), progesterone (PgR) and human epidermal growth factor receptor-2 (HER-2) receptors were considered in this evaluation. The results demonstrated that CXCL8, CXCL10 and CXCL16 showed a significant increased median in BC and BBL patients compared to control (CXCL8: 47.3 and 25.7 vs. 15.0; CXCL10: 37.6 and 30.7 vs. 13.1; CXCL16; 27.9 and 25.2 vs. 19.2 pg/ml, respectively). The increased levels of CXCL8 and CXCL16 were more pronounced in triple-negative and HER-2 positive patients, respectively. Binary logistic regression analysis revealed that CXCL8 was a significant predictor of BC, and such prediction was more depicted in triple-negative patients. The receiver operating characteristic analysis also revealed that CXCL8 recorded an area under curve of 0.998 in BC patients. In conclusion, CXCL8 is a potential biomarker for BC, especially when ER, PgR and HER-2 expression is considered. In this context, the predictive significance of CXCL8 in influencing BC progression is suggested in triple-negative patients. Breast cancer, Benign breast lesion, CXCL8, CXCL10, CXCL16 Science Q Munawar A Al-naqqash verfasserin aut Nada A Alawn verfasserin aut Ali H Ad'hiah verfasserin aut In Baghdad Science Journal College of Science for Women, University of Baghdad, 2017 17(2020), 1(Suppl.) (DE-627)756826632 (DE-600)2727652-1 24117986 nnns volume:17 year:2020 number:1(Suppl.) https://doi.org/10.21123/bsj.2020.17.1(Suppl.).0199 kostenfrei https://doaj.org/article/7b68ea0c0dce4556be436da6da38c644 kostenfrei http://bsj.uobaghdad.edu.iq/index.php/BSJ/article/view/3052 kostenfrei https://doaj.org/toc/2078-8665 Journal toc kostenfrei https://doaj.org/toc/2411-7986 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4335 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 17 2020 1(Suppl.)
allfieldsGer	10.21123/bsj.2020.17.1(Suppl.).0199 doi (DE-627)DOAJ023964456 (DE-599)DOAJ7b68ea0c0dce4556be436da6da38c644 DE-627 ger DE-627 rakwb ara eng Aseel F Khalaf verfasserin aut Biomarker Significance of Serum CXCL8, CXCL10 and CXCL16 in Breast Tumors of Iraqi Patients 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The biomarker significance of three chemokines (CXCL8, CXCL10 and CXCL16) was evaluated in sera of 45 breast cancer (BC) and 28 benign breast lesion (BBL) patients, as well as 20 control women. Clinical stage and tumor expression of estrogen (ER), progesterone (PgR) and human epidermal growth factor receptor-2 (HER-2) receptors were considered in this evaluation. The results demonstrated that CXCL8, CXCL10 and CXCL16 showed a significant increased median in BC and BBL patients compared to control (CXCL8: 47.3 and 25.7 vs. 15.0; CXCL10: 37.6 and 30.7 vs. 13.1; CXCL16; 27.9 and 25.2 vs. 19.2 pg/ml, respectively). The increased levels of CXCL8 and CXCL16 were more pronounced in triple-negative and HER-2 positive patients, respectively. Binary logistic regression analysis revealed that CXCL8 was a significant predictor of BC, and such prediction was more depicted in triple-negative patients. The receiver operating characteristic analysis also revealed that CXCL8 recorded an area under curve of 0.998 in BC patients. In conclusion, CXCL8 is a potential biomarker for BC, especially when ER, PgR and HER-2 expression is considered. In this context, the predictive significance of CXCL8 in influencing BC progression is suggested in triple-negative patients. Breast cancer, Benign breast lesion, CXCL8, CXCL10, CXCL16 Science Q Munawar A Al-naqqash verfasserin aut Nada A Alawn verfasserin aut Ali H Ad'hiah verfasserin aut In Baghdad Science Journal College of Science for Women, University of Baghdad, 2017 17(2020), 1(Suppl.) (DE-627)756826632 (DE-600)2727652-1 24117986 nnns volume:17 year:2020 number:1(Suppl.) https://doi.org/10.21123/bsj.2020.17.1(Suppl.).0199 kostenfrei https://doaj.org/article/7b68ea0c0dce4556be436da6da38c644 kostenfrei http://bsj.uobaghdad.edu.iq/index.php/BSJ/article/view/3052 kostenfrei https://doaj.org/toc/2078-8665 Journal toc kostenfrei https://doaj.org/toc/2411-7986 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4335 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 17 2020 1(Suppl.)
allfieldsSound	10.21123/bsj.2020.17.1(Suppl.).0199 doi (DE-627)DOAJ023964456 (DE-599)DOAJ7b68ea0c0dce4556be436da6da38c644 DE-627 ger DE-627 rakwb ara eng Aseel F Khalaf verfasserin aut Biomarker Significance of Serum CXCL8, CXCL10 and CXCL16 in Breast Tumors of Iraqi Patients 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The biomarker significance of three chemokines (CXCL8, CXCL10 and CXCL16) was evaluated in sera of 45 breast cancer (BC) and 28 benign breast lesion (BBL) patients, as well as 20 control women. Clinical stage and tumor expression of estrogen (ER), progesterone (PgR) and human epidermal growth factor receptor-2 (HER-2) receptors were considered in this evaluation. The results demonstrated that CXCL8, CXCL10 and CXCL16 showed a significant increased median in BC and BBL patients compared to control (CXCL8: 47.3 and 25.7 vs. 15.0; CXCL10: 37.6 and 30.7 vs. 13.1; CXCL16; 27.9 and 25.2 vs. 19.2 pg/ml, respectively). The increased levels of CXCL8 and CXCL16 were more pronounced in triple-negative and HER-2 positive patients, respectively. Binary logistic regression analysis revealed that CXCL8 was a significant predictor of BC, and such prediction was more depicted in triple-negative patients. The receiver operating characteristic analysis also revealed that CXCL8 recorded an area under curve of 0.998 in BC patients. In conclusion, CXCL8 is a potential biomarker for BC, especially when ER, PgR and HER-2 expression is considered. In this context, the predictive significance of CXCL8 in influencing BC progression is suggested in triple-negative patients. Breast cancer, Benign breast lesion, CXCL8, CXCL10, CXCL16 Science Q Munawar A Al-naqqash verfasserin aut Nada A Alawn verfasserin aut Ali H Ad'hiah verfasserin aut In Baghdad Science Journal College of Science for Women, University of Baghdad, 2017 17(2020), 1(Suppl.) (DE-627)756826632 (DE-600)2727652-1 24117986 nnns volume:17 year:2020 number:1(Suppl.) https://doi.org/10.21123/bsj.2020.17.1(Suppl.).0199 kostenfrei https://doaj.org/article/7b68ea0c0dce4556be436da6da38c644 kostenfrei http://bsj.uobaghdad.edu.iq/index.php/BSJ/article/view/3052 kostenfrei https://doaj.org/toc/2078-8665 Journal toc kostenfrei https://doaj.org/toc/2411-7986 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4335 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 17 2020 1(Suppl.)
language	Arabic English
source	In Baghdad Science Journal 17(2020), 1(Suppl.) volume:17 year:2020 number:1(Suppl.)
sourceStr	In Baghdad Science Journal 17(2020), 1(Suppl.) volume:17 year:2020 number:1(Suppl.)
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	Breast cancer, Benign breast lesion, CXCL8, CXCL10, CXCL16 Science Q
isfreeaccess_bool	true
container_title	Baghdad Science Journal
authorswithroles_txt_mv	Aseel F Khalaf @@aut@@ Munawar A Al-naqqash @@aut@@ Nada A Alawn @@aut@@ Ali H Ad'hiah @@aut@@
publishDateDaySort_date	2020-01-01T00:00:00Z
hierarchy_top_id	756826632
id	DOAJ023964456
language_de	arabisch englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ023964456</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230307071740.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230226s2020 xx \|\|\|\|\|o 00\| \|\|ara c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.21123/bsj.2020.17.1(Suppl.).0199</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ023964456</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ7b68ea0c0dce4556be436da6da38c644</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">ara</subfield><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Aseel F Khalaf</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Biomarker Significance of Serum CXCL8, CXCL10 and CXCL16 in Breast Tumors of Iraqi Patients</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The biomarker significance of three chemokines (CXCL8, CXCL10 and CXCL16) was evaluated in sera of 45 breast cancer (BC) and 28 benign breast lesion (BBL) patients, as well as 20 control women. Clinical stage and tumor expression of estrogen (ER), progesterone (PgR) and human epidermal growth factor receptor-2 (HER-2) receptors were considered in this evaluation. The results demonstrated that CXCL8, CXCL10 and CXCL16 showed a significant increased median in BC and BBL patients compared to control (CXCL8: 47.3 and 25.7 vs. 15.0; CXCL10: 37.6 and 30.7 vs. 13.1; CXCL16; 27.9 and 25.2 vs. 19.2 pg/ml, respectively). The increased levels of CXCL8 and CXCL16 were more pronounced in triple-negative and HER-2 positive patients, respectively. Binary logistic regression analysis revealed that CXCL8 was a significant predictor of BC, and such prediction was more depicted in triple-negative patients. The receiver operating characteristic analysis also revealed that CXCL8 recorded an area under curve of 0.998 in BC patients. In conclusion, CXCL8 is a potential biomarker for BC, especially when ER, PgR and HER-2 expression is considered. In this context, the predictive significance of CXCL8 in influencing BC progression is suggested in triple-negative patients.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Breast cancer, Benign breast lesion, CXCL8, CXCL10, CXCL16</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Science</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Q</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Munawar A Al-naqqash</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Nada A Alawn</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ali H Ad'hiah</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Baghdad Science Journal</subfield><subfield code="d">College of Science for Women, University of Baghdad, 2017</subfield><subfield code="g">17(2020), 1(Suppl.)</subfield><subfield code="w">(DE-627)756826632</subfield><subfield code="w">(DE-600)2727652-1</subfield><subfield code="x">24117986</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:17</subfield><subfield code="g">year:2020</subfield><subfield code="g">number:1(Suppl.)</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.21123/bsj.2020.17.1(Suppl.).0199</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/7b68ea0c0dce4556be436da6da38c644</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://bsj.uobaghdad.edu.iq/index.php/BSJ/article/view/3052</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2078-8665</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2411-7986</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_171</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4335</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">17</subfield><subfield code="j">2020</subfield><subfield code="e">1(Suppl.)</subfield></datafield></record></collection>
author	Aseel F Khalaf
spellingShingle	Aseel F Khalaf misc Breast cancer, Benign breast lesion, CXCL8, CXCL10, CXCL16 misc Science misc Q Biomarker Significance of Serum CXCL8, CXCL10 and CXCL16 in Breast Tumors of Iraqi Patients
authorStr	Aseel F Khalaf
ppnlink_with_tag_str_mv	@@773@@(DE-627)756826632
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut
collection	DOAJ
remote_str	true
illustrated	Not Illustrated
issn	24117986
topic_title	Biomarker Significance of Serum CXCL8, CXCL10 and CXCL16 in Breast Tumors of Iraqi Patients Breast cancer, Benign breast lesion, CXCL8, CXCL10, CXCL16
topic	misc Breast cancer, Benign breast lesion, CXCL8, CXCL10, CXCL16 misc Science misc Q
topic_unstemmed	misc Breast cancer, Benign breast lesion, CXCL8, CXCL10, CXCL16 misc Science misc Q
topic_browse	misc Breast cancer, Benign breast lesion, CXCL8, CXCL10, CXCL16 misc Science misc Q
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Baghdad Science Journal
hierarchy_parent_id	756826632
hierarchy_top_title	Baghdad Science Journal
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)756826632 (DE-600)2727652-1
title	Biomarker Significance of Serum CXCL8, CXCL10 and CXCL16 in Breast Tumors of Iraqi Patients
ctrlnum	(DE-627)DOAJ023964456 (DE-599)DOAJ7b68ea0c0dce4556be436da6da38c644
title_full	Biomarker Significance of Serum CXCL8, CXCL10 and CXCL16 in Breast Tumors of Iraqi Patients
author_sort	Aseel F Khalaf
journal	Baghdad Science Journal
journalStr	Baghdad Science Journal
lang_code	ara eng
isOA_bool	true
recordtype	marc
publishDateSort	2020
contenttype_str_mv	txt
author_browse	Aseel F Khalaf Munawar A Al-naqqash Nada A Alawn Ali H Ad'hiah
container_volume	17
format_se	Elektronische Aufsätze
author-letter	Aseel F Khalaf
doi_str_mv	10.21123/bsj.2020.17.1(Suppl.).0199
author2-role	verfasserin
title_sort	biomarker significance of serum cxcl8, cxcl10 and cxcl16 in breast tumors of iraqi patients
title_auth	Biomarker Significance of Serum CXCL8, CXCL10 and CXCL16 in Breast Tumors of Iraqi Patients
abstract	The biomarker significance of three chemokines (CXCL8, CXCL10 and CXCL16) was evaluated in sera of 45 breast cancer (BC) and 28 benign breast lesion (BBL) patients, as well as 20 control women. Clinical stage and tumor expression of estrogen (ER), progesterone (PgR) and human epidermal growth factor receptor-2 (HER-2) receptors were considered in this evaluation. The results demonstrated that CXCL8, CXCL10 and CXCL16 showed a significant increased median in BC and BBL patients compared to control (CXCL8: 47.3 and 25.7 vs. 15.0; CXCL10: 37.6 and 30.7 vs. 13.1; CXCL16; 27.9 and 25.2 vs. 19.2 pg/ml, respectively). The increased levels of CXCL8 and CXCL16 were more pronounced in triple-negative and HER-2 positive patients, respectively. Binary logistic regression analysis revealed that CXCL8 was a significant predictor of BC, and such prediction was more depicted in triple-negative patients. The receiver operating characteristic analysis also revealed that CXCL8 recorded an area under curve of 0.998 in BC patients. In conclusion, CXCL8 is a potential biomarker for BC, especially when ER, PgR and HER-2 expression is considered. In this context, the predictive significance of CXCL8 in influencing BC progression is suggested in triple-negative patients.
abstractGer	The biomarker significance of three chemokines (CXCL8, CXCL10 and CXCL16) was evaluated in sera of 45 breast cancer (BC) and 28 benign breast lesion (BBL) patients, as well as 20 control women. Clinical stage and tumor expression of estrogen (ER), progesterone (PgR) and human epidermal growth factor receptor-2 (HER-2) receptors were considered in this evaluation. The results demonstrated that CXCL8, CXCL10 and CXCL16 showed a significant increased median in BC and BBL patients compared to control (CXCL8: 47.3 and 25.7 vs. 15.0; CXCL10: 37.6 and 30.7 vs. 13.1; CXCL16; 27.9 and 25.2 vs. 19.2 pg/ml, respectively). The increased levels of CXCL8 and CXCL16 were more pronounced in triple-negative and HER-2 positive patients, respectively. Binary logistic regression analysis revealed that CXCL8 was a significant predictor of BC, and such prediction was more depicted in triple-negative patients. The receiver operating characteristic analysis also revealed that CXCL8 recorded an area under curve of 0.998 in BC patients. In conclusion, CXCL8 is a potential biomarker for BC, especially when ER, PgR and HER-2 expression is considered. In this context, the predictive significance of CXCL8 in influencing BC progression is suggested in triple-negative patients.
abstract_unstemmed	The biomarker significance of three chemokines (CXCL8, CXCL10 and CXCL16) was evaluated in sera of 45 breast cancer (BC) and 28 benign breast lesion (BBL) patients, as well as 20 control women. Clinical stage and tumor expression of estrogen (ER), progesterone (PgR) and human epidermal growth factor receptor-2 (HER-2) receptors were considered in this evaluation. The results demonstrated that CXCL8, CXCL10 and CXCL16 showed a significant increased median in BC and BBL patients compared to control (CXCL8: 47.3 and 25.7 vs. 15.0; CXCL10: 37.6 and 30.7 vs. 13.1; CXCL16; 27.9 and 25.2 vs. 19.2 pg/ml, respectively). The increased levels of CXCL8 and CXCL16 were more pronounced in triple-negative and HER-2 positive patients, respectively. Binary logistic regression analysis revealed that CXCL8 was a significant predictor of BC, and such prediction was more depicted in triple-negative patients. The receiver operating characteristic analysis also revealed that CXCL8 recorded an area under curve of 0.998 in BC patients. In conclusion, CXCL8 is a potential biomarker for BC, especially when ER, PgR and HER-2 expression is considered. In this context, the predictive significance of CXCL8 in influencing BC progression is suggested in triple-negative patients.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4335 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	1(Suppl.)
title_short	Biomarker Significance of Serum CXCL8, CXCL10 and CXCL16 in Breast Tumors of Iraqi Patients
url	https://doi.org/10.21123/bsj.2020.17.1(Suppl.).0199 https://doaj.org/article/7b68ea0c0dce4556be436da6da38c644 http://bsj.uobaghdad.edu.iq/index.php/BSJ/article/view/3052 https://doaj.org/toc/2078-8665 https://doaj.org/toc/2411-7986
remote_bool	true
author2	Munawar A Al-naqqash Nada A Alawn Ali H Ad'hiah
author2Str	Munawar A Al-naqqash Nada A Alawn Ali H Ad'hiah
ppnlink	756826632
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.21123/bsj.2020.17.1(Suppl.).0199
up_date	2024-07-03T20:27:35.506Z
_version_	1803591043527999489
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ023964456</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230307071740.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230226s2020 xx \|\|\|\|\|o 00\| \|\|ara c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.21123/bsj.2020.17.1(Suppl.).0199</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ023964456</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ7b68ea0c0dce4556be436da6da38c644</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">ara</subfield><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Aseel F Khalaf</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Biomarker Significance of Serum CXCL8, CXCL10 and CXCL16 in Breast Tumors of Iraqi Patients</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The biomarker significance of three chemokines (CXCL8, CXCL10 and CXCL16) was evaluated in sera of 45 breast cancer (BC) and 28 benign breast lesion (BBL) patients, as well as 20 control women. Clinical stage and tumor expression of estrogen (ER), progesterone (PgR) and human epidermal growth factor receptor-2 (HER-2) receptors were considered in this evaluation. The results demonstrated that CXCL8, CXCL10 and CXCL16 showed a significant increased median in BC and BBL patients compared to control (CXCL8: 47.3 and 25.7 vs. 15.0; CXCL10: 37.6 and 30.7 vs. 13.1; CXCL16; 27.9 and 25.2 vs. 19.2 pg/ml, respectively). The increased levels of CXCL8 and CXCL16 were more pronounced in triple-negative and HER-2 positive patients, respectively. Binary logistic regression analysis revealed that CXCL8 was a significant predictor of BC, and such prediction was more depicted in triple-negative patients. The receiver operating characteristic analysis also revealed that CXCL8 recorded an area under curve of 0.998 in BC patients. In conclusion, CXCL8 is a potential biomarker for BC, especially when ER, PgR and HER-2 expression is considered. In this context, the predictive significance of CXCL8 in influencing BC progression is suggested in triple-negative patients.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Breast cancer, Benign breast lesion, CXCL8, CXCL10, CXCL16</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Science</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Q</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Munawar A Al-naqqash</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Nada A Alawn</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ali H Ad'hiah</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Baghdad Science Journal</subfield><subfield code="d">College of Science for Women, University of Baghdad, 2017</subfield><subfield code="g">17(2020), 1(Suppl.)</subfield><subfield code="w">(DE-627)756826632</subfield><subfield code="w">(DE-600)2727652-1</subfield><subfield code="x">24117986</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:17</subfield><subfield code="g">year:2020</subfield><subfield code="g">number:1(Suppl.)</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.21123/bsj.2020.17.1(Suppl.).0199</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/7b68ea0c0dce4556be436da6da38c644</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://bsj.uobaghdad.edu.iq/index.php/BSJ/article/view/3052</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2078-8665</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2411-7986</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_171</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4335</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">17</subfield><subfield code="j">2020</subfield><subfield code="e">1(Suppl.)</subfield></datafield></record></collection>
score	7.399638

Nicht das Richtige dabei?

Schreiben Sie uns!

Biomarker Significance of Serum CXCL8, CXCL10 and CXCL16 in Breast Tumors of Iraqi Patients

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?